---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-015944"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T08:04:38.662027+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision reports nine-month revenue of $314K; cash at $5.6M

## Summary
- Nine-month revenue $314K; total assets $32.9M; cash $5.6M as of Sep 30, 2023.
- Received first approval in France; VIVO now active in six European countries.
- Completed enrollment of Phase I LockeT study (>100 patients); IRB approval for Phase II randomized study.
- Initiated design changes to LockeT based on feedback; new build processes for VIVO to reduce costs.
- Acting CEO David Jenkins expects hospital approvals and purchase orders in coming months.

## SEC filing metadata
- accession: 0001654954-23-015944
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/0001654954-23-015944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/rmed_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-015944
- JSON: https://secwatch.observer/filing/0001654954-23-015944.json
- Plain text: https://secwatch.observer/filing/0001654954-23-015944.txt

## Key facts
- Earnings Releases
  Catheter Precision, Inc. reported three and nine months ended September 30, 2023 results: revenue $314 thousand.
  - Period: three and nine months ended September 30, 2023
  - Revenue: $314 thousand
  - Result: reported results
  source text: assets at September 30, 2023, were $32.9 million. · Total cash on hand at September 30, 2023 was $5.6 million. · Total revenues for the nine months ended September 30, 2023 were $314 thousand. David Jenkins, acting CEO, commented: “We are pleased to have the Q3 financial filings completed and have a lot of momentum as we move into the fourth quarter. Our sales and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/0001654954-23-015944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.